PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred a ...

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher. The chief executives of Johnson & Johnson JNJ, -0.96%, Merck & Co. MRK, -0.63% and Bristol Myers Squibb Co. BMY, -0.05% were faced with sharp questioning from Sen. Bernie Sanders, the Vermont independent, and other members of the Senate Health, Education, Labor and Pensions Committee demanding to know why U.S. p ...

Jazz Pharmaceuticals plc (JAZZ) announced that it has entered into a definitive agreement with U.K.-based biotech Redx Pharma to acquire global rights to the latter’s preclinical KRAS (Kirsten rat sarcoma virus) inhibitor program.Per the agreement, Jazz will make an upfront payment of $10 million to Redx to gain all rights, patents and interest related to its proprietary KRAS inhibitor program, including its G12D selective and pan-KRAS molecules.Further, Redx is entitled to receive up to $870 million in the ...

ToplineChief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.), who has accused the firms of overcharging Americans for prescription drugs.Johnson & Johnson and Merck have accused Sen. Bernie Sanders of unjustly targeting the companies.getty Key FactsJohnson & Johnson CEO Joaquin Duato, Merck CEO Robert Davis and Bristol Myers Squibb CEO Chris Boerner will testify before the Senate Committee on ...

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. The push to cut drug prices is one of those rare hot-button issues that unites the two major poli ...

Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say. The CEOs of Merck & Co. Inc. MRK, +0.49%, Johnson & Johnson JNJ, -0.11% and Bristol Myers Squibb Co. BMY, -1.50% are set to appear before the Senate Health, Education, Labor and Pensions Committee on Thursday for a hearing examining why U.S. prescription-drug prices are far higher than those in other countries. Merck CEO Robert Davis a ...

Bristol Myers Squibb (BMY) and its partner 2seventy bio, Inc. (TSVT) announced that a notice was published in the Federal Register that the FDA will convene a virtual meeting of the Oncologic Drugs Advisory Committee (“ODAC”) on Mar 15, 2024, to review data supporting the supplemental biologics license application (sBLA) for Abecma (idecabtagene vicleucel).The sBLA is seeking label expansion of Abecma for triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal p ...

Biopharmaceutical stock Bristol-Myers Squibb Co (NYSE:BMY) is in focus this morning, after a downgrade to "neutral" from "buy" at Redburn-Atlantic. The analyst in coverage also lowered its price target to $54 from $77 -- still a 12.6% premium to last night's close at $47.98. BMY is fractionally lower before the open.The Wall Street analyst cited concerns regarding Bristol-Myers Squibb's product pipeline and market challenges. It argued that any positive impact from the company's recent acquisitions won't be ...

In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $47.68 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF back on 12/31/1999 — you would have paid $146.88 per share. Fast ...

BALA CYNWYD, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Catalent, Inc. (NYSE – CTLT) Under the terms of the agreement, Catalent will be acquired by Novo Holdings. Catalent shareholders will receive $63.50 per share in cash in a de ...